A randomized clinical trial in which both survival and longitudinal data were collected to compare the efficacy and
safety of two antiretroviral drugs, namely
ddI (didanosine) and
ddC (zalcitabine), in treating HIV-infected patients intolerant or failing zidovudine (AZT) therapy.
A data frame with 1405 observations on the following 12 variables.
patient ID, there are 467 patients in total.
survival time, i.e. time to death or censoring.
death indicator: 0 denotes censoring; 1 denotes death.
time points at which the longitudinal measurements, i.e. CD4 cell counts, are recorded.
CD4 cell counts measured at
drug indicator with two levels:
gender indicator with two levels:
AIDS diagnosis at study entry indicator with two levels:
AZT intolerance/failure indicator with two levels:
obstime, starting time of the interval which contains the time of the CD4 cell count measurement.
ending time of the interval which contains the time of the CD4 cell count measurement.
event indicator suggesting whether the event-of-interest, i.e. death, happens in the interval given by
Goldman, A., Carlin, B., Crane, L., Launer, C., Korvick, J., Deyton, L. and Abrams, D. (1996) Response of CD4+ and clinical consequences to treatment using ddI or ddC in patients with advanced HIV infection. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 11, 161–169.
Guo, X. and Carlin, B. (2004) Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician 58, 16–24.
Xu, C., Baines, P. D. and Wang, J. L. (2014) Standard error estimation using the EM algorithm for the joint modeling of survival and longitudinal data. Biostatistics 15, 731–744
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.